Norwegian deep tech startup brings its Series A to $28 million for clinical advancement of CyPep-1, a first-in-class targeted tumor membrane immunotherapy
Bergen-based clinical stage immune-oncology startup Cytovation ASA has successfully secured an additional $8 million (NOK 85M) in a Series A funding round,